- Home
- BGLC vs CVKD Comparison
BGLC vs CVKD Comparison
Compare BGLC & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- CVKD
- Stock Information
- Founded
- BGLC 2017
- CVKD 2022
- Country
- BGLC Malaysia
- CVKD United States
- Employees
- BGLC N/A
- CVKD N/A
- Industry
- BGLC Medical Specialities
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- BGLC Health Care
- CVKD Health Care
- Exchange
- BGLC Nasdaq
- CVKD Nasdaq
- Market Cap
- BGLC 5.0M
- CVKD 29.5M
- IPO Year
- BGLC N/A
- CVKD 2023
- Fundamental
- Price
- BGLC $6.41
- CVKD $12.80
- Analyst Decision
- BGLC
- CVKD Strong Buy
- Analyst Count
- BGLC 0
- CVKD 1
- Target Price
- BGLC N/A
- CVKD $32.00
- AVG Volume (30 Days)
- BGLC 2.7M
- CVKD 32.3K
- Earning Date
- BGLC 08-13-2025
- CVKD 08-06-2025
- Dividend Yield
- BGLC N/A
- CVKD N/A
- EPS Growth
- BGLC N/A
- CVKD N/A
- EPS
- BGLC N/A
- CVKD N/A
- Revenue
- BGLC $9,265,870.00
- CVKD N/A
- Revenue This Year
- BGLC N/A
- CVKD N/A
- Revenue Next Year
- BGLC N/A
- CVKD N/A
- P/E Ratio
- BGLC N/A
- CVKD N/A
- Revenue Growth
- BGLC N/A
- CVKD N/A
- 52 Week Low
- BGLC $2.01
- CVKD $5.70
- 52 Week High
- BGLC $15.60
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- BGLC 60.18
- CVKD 49.60
- Support Level
- BGLC $5.56
- CVKD $11.00
- Resistance Level
- BGLC $15.60
- CVKD $13.71
- Average True Range (ATR)
- BGLC 0.96
- CVKD 1.14
- MACD
- BGLC 0.52
- CVKD 0.10
- Stochastic Oscillator
- BGLC 29.46
- CVKD 63.54
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.